Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board

Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in Renal Innovation

Shanghai, China, June 29, 2026 — Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a biopharmaceutical company focused on kidney disease, with the broadest pipeline by renal indication coverage, today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The Global Offering marks Alebund's entry into the international capital markets, positioning the Company as a scarce, innovation-driven renal-focused asset in Hong Kong's capital market.The Global Offering comprised a total of 56,755,400 H Shares at an Offer Price of HK$22.60 per Offer Share, consisting of 5,675,600 H Shares under the Hong Kong Public Offering and 51,079,800 H Shares under the International Offering. Without taking into account any exercise of the Over-allotment Option (the "Greenshoe"), total gross proceeds amounted to approximately HK$1.283 billion (approximately US$164 million). If the Over-allotment Option (up to 8,513,300 H Shares) is exercised in full, the total gross proceeds will increase to approximately HK$1.475 billion (approximately US$189 million). After deducting offering expenses, the Company estimates that the net proceeds from the Global Offering will be approximately HK$1.181 billion.

Following the market open today, Alebund's shares show strong performance; as of the close, the share price rose 103.54%, closing at HK$46.0 per share.

Alebund Pharmaceuticals lists on the Main Board of The Stock Exchange of Hong Kong Limited

The Global Offering attracted a strong line-up of cornerstone investors, including GIC, Loomis Sayles, RTW, SymBiosis, Tencent, Cormorant, Dymon Asia, GF Fund, China Universal, E Fund and Loyal Valley Capital, among other renowned institutions. The cornerstone investors subscribed for a total of approximately US$81.5 million (approximately HK$639 million), representing approximately 49.78% of the shares offered under the Global Offering. The International Offering was approximately 19.77 times oversubscribed, and the Hong Kong Public Offering was approximately 963.56 times oversubscribed, reflecting enthusiastic demand. The strong cornerstone line-up and robust market response fully demonstrate the global capital markets' high recognition of the scarcity value of Alebund's innovative renal pipeline, as well as their firm confidence in the Company's core value and long-term development potential.

A Broad and Well-Balanced Renal Innovation Pipeline

Alebund has built the industry's broadest pipeline in terms of kidney disease indication coverage:

AP301 is a best-in-class oral phosphate binder for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis, with its registrational Phase III trial in China having met the primary endpoint, a New Drug Application (NDA) to the National Medical Products Administration (NMPA) planned for the near future, and its China-U.S. Phase III multi-regional clinical trial (MRCT) having completed enrollment.

AP306 is a first-in-class pan-phosphate transporter inhibitor that has received Breakthrough Therapy Designation (BTD) from the NMPA and whose rights outside Chinese Mainland, Hong Kong, Macau and Taiwan have been licensed to R1 Therapeutics. China Phase II data demonstrated monotherapy reducing mean serum phosphate by 2.51 mg/dL from baseline and approximately 95% of patients achieving serum phosphate below 5.5 mg/dL by Week 7-8 (versus approximately 50% for the active control, sevelamer carbonate, in the same trial).

AP303 is a first-in-class, differentiated dual PPAR agonist designed to delay or halt the progression of CKD across potential indications including diabetic kidney disease (DKD) and IgA nephropathy (IgAN), and has received Orphan Drug Designation (ODD) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) from the U.S. FDA. In the completed Phase I trials in Australia and China, AP303 demonstrated favorable safety and was well tolerated in healthy volunteers as well as in patients with DKD, and there was a clear and robust dose-dependent pharmacodynamic ("PD") signal. Alebund has received IND clearance from the NMPA and the FDA for AP303, and expects to conduct a basket Phase II clinical trial in DKD and IgAN patients in the second half of 2026.

AP308 is a first-in-class engineered recombinant IgA protease aiming for a functional cure of IgAN. The Company plans to submit an IND to the U.S. FDA and China's NMPA in the third quarter of 2026 and to enter the clinical development stage.

The Company's commercialized renal anemia product Mircera®, a long-acting ESA (erythropoiesis-stimulating agent), continues to gain traction, marking Alebund's accelerating transition from biotech to biopharma.

Focusing on the "Silent Majority" and Addressing Vast Unmet Needs

Kidney disease is a long-underestimated field with vast unmet clinical needs. There are more than 800 million people living with chronic kidney disease worldwide, including nearly 124 million patients in China. Taking hyperphosphatemia as an example, approximately 76% of dialysis patients in China have uncontrolled serum phosphate levels — far higher than in the United States (52%) and Japan (39%) — reflecting a treatment need that is real, long-term and structural. Alebund firmly focuses on kidney disease, the "silent majority," committed to providing higher-quality and more accessible treatment options for kidney disease patients worldwide.

Messages from Management

Dr. Gavin Xia, Co-founder, Chief Executive Officer and Chairman of the Board of Alebund, said: "Listing on the Main Board of The Stock Exchange of Hong Kong Limited is an important milestone in Alebund's journey. Alebund's rapid growth and successful listing on the Hong Kong Stock Exchange would not have been possible without the relentless efforts of our team, nor without the support of government authorities at all levels, our investors, and partners across all sectors. From this new starting point, Alebund will continue to accelerate the clinical and commercialization progress of its product pipeline, further upgrade its globally competitive integrated kidney disease platform, reward shareholders and partners with even stronger performance, and safeguard patients worldwide with higher-quality kidney disease treatment solutions."

Dr. Jin Tian, Co-founder and Chief Medical Officer of Alebund, said: "Alebund is dedicated to overcoming the persistent therapeutic challenges associated with chronic kidney disease and has established a highly differentiated and innovative product pipeline. Our lead asset, AP301, has successfully completed a Phase III registrational trial in China and is on track for New Drug Application (NDA) submission, which we expect to provide a better option for the management of hyperphosphatemia in patients receiving dialysis. In parallel, we are rapidly advancing the clinical development of our follow-up pipeline candidates, striving to bring next-generation therapies to patients with renal disease as quickly as possible.", said: "Alebund is dedicated to overcoming the persistent therapeutic

challenges associated with chronic kidney disease and has established a highly differentiated and innovative product pipeline. Our lead asset, AP301, has successfully completed a Phase III registrational trial in China and is on track for New Drug Application (NDA) submission, which we expect to provide a better option for the management of hyperphosphatemia in patients receiving dialysis. In parallel, we are rapidly advancing the clinical development of our follow-up pipeline candidates, striving to bring next-generation therapies to patients with renal disease as quickly as possible."

About Alebund Pharmaceuticals

Alebund Pharmaceuticals (09637.HK) was established in Shanghai, China in early 2018. It is a biopharmaceutical company focused on kidney disease and related chronic diseases, with the broadest pipeline in terms of renal indication coverage, principally engaged in the discovery, development, manufacturing and commercialization of innovative drugs in these areas, with the aim of providing better clinical treatment solutions for patients with chronic kidney disease and related diseases worldwide. Alebund has established a rich and well-balanced pipeline of innovative kidney disease drugs, including seven product candidates and one commercialized product (Mircera®), with indications spanning hyperphosphatemia, renal anemia, IgA nephropathy (IgAN), diabetic kidney disease (DKD), focal segmental glomerulosclerosis (FSGS) and autosomal dominant polycystic kidney disease (ADPKD), among others. The Company has built and commenced operations at a manufacturing facility in Yangzhou, Jiangsu, which has obtained a Drug Manufacturing License (Category B) issued by the Jiangsu Provincial Drug Administration, to support the future commercialization of AP301 and other pipeline products. The Company has also established a specialized nephrology sales team responsible for the commercialization of related products in China.

礼邦医药（09637.HK）正式在香港联合交易所主板挂牌上市

持续深耕肾脏疾病赛道，加速迈向全球肾病创新引领者

中国 · 上海，2026 年 6 月 29 日 —— 聚焦肾脏疾病的综合性创新生物制药公司礼邦医药（江苏）股份有限公司（以下简称“礼邦医药”或“公司”，股票代码：09637.HK）于今日正式在香港联合交易所主板挂牌上市，礼邦医药由此正式登陆国际资本市场，成为港股市场中专注肾脏病领域的稀缺创新标的。

本次全球发售共发行 56,755,400 股 H 股，发行价为每股 22.60 港元，其中香港公开发售 5,675,600 股、国际发售 51,079,800 股。绿鞋前募资总额约 12.83 亿港元（约 1.64 亿美元）；若超额配股权（绿鞋，最多 8,513,300 股）获全数行使，发行规模将扩大至约 14.75 亿港元（约 1.89 亿美元）。扣除发行费用后，公司估计全球发售所得款项净额约为 11.81 亿港元。

今日开盘后，礼邦医药市场表现强劲，截至收盘股价上涨 103.54%，收盘报 46.0 港元 / 股。

礼邦医药于香港联合交易所主板挂牌上市

本次发售引入阵容强大的基石投资者，包括 GIC、Loomis Sayles、RTW、SymBiosis、腾讯、Cormorant、Dymon Asia、广发基金、汇添富、易方达及正心谷等知名机构。基石投资认购总额约 8,150 万美元（约 6.39 亿港元），约占全球发售股份的 49.78%。本项目国

际配售获 19.77 倍认购，香港公开发售亦录得 963.56 倍认购，认购踊跃。强大的基石阵容与踊跃的市场反应，充分彰显了全球资本市场对礼邦医药肾病创新管线稀缺价值的高度认可，以及对公司核心价值与长远发展潜力的坚定信心。

覆盖广泛、布局均衡的肾病创新管线

礼邦医药已建立起业内覆盖肾脏病适应症最为广泛的产品管线：

AP301 为治疗慢性肾脏病（CKD）透析患者高磷血症的同类最优（best-in-class）口服磷结合剂，在中国用于注册申请的关键 III 期临床试验已达到主要终点，计划于近期向国家药品监督管理局（NMPA）递交新药上市申请（NDA）；此外，同步推进的中美 III 期国际多中心临床试验（MRCT）已完成入组。

AP306 为同类首创（first-in-class）泛磷酸盐转运蛋白抑制剂，已获 NMPA 突破性治疗药物（BTD）认定，并将中国大陆、香港、澳门及台湾以外权益授权予 R1 Therapeutics。中国 II 期数据显示，AP306 单药治疗可使平均血清磷较基线下降 2.51 mg/dL，约 95%的患者在第 7 至 8 周将血清磷控制于 5.5 mg/dL 以下，而同期阳性对照碳酸司维拉姆组这一比例约为 50%。

AP303 为同类首创（first-in-class）差异化双重 PPAR 激动剂，旨在延缓或阻止 CKD 进展，潜在覆盖适应症包括糖尿病肾病（DKD）与 IgA 肾病（IgAN）等，已获美国 FDA 授予的常染色体显性多囊性肾病（ADPKD）的孤儿药资格认定（ODD）。在澳大利亚和中国已完成的 I 期临床试验中，AP303 在健康志愿者和糖尿病肾病患者中表现出良好的安全性和耐受性，且呈现清晰、显著的剂量依赖性的药效动力学（“PD”）信号。目前，AP303 已获得 NMPA 及美国 FDA 的 IND 许可，预计于 2026 年下半年开展针对 DKD 及 IgAN 患者的篮式 II 期临床试验。

AP308 为同类首创（first-in-class）工程化重组 IgA 蛋白酶，旨在实现 IgAN 功能性治愈，预计于 2026 年第三季度在美国和中国递交 IND 申请并进入临床开发阶段。

已商业化的肾性贫血产品美信罗®（Mircera®）持续放量，标志着礼邦医药正加速由 Biotech 向 Biopharma 跨越。

聚焦“沉默的大多数”，直面巨大未满足需求

肾脏病是一个长期被低估、临床未满足需求巨大的领域。全球慢性肾脏病患者总数已逾 8 亿，其中中国患者数量近 1.24 亿。以高磷血症为例，中国约 76% 的透析患者血磷水平未达标，远高于美国（52%）与日本（39%），治疗需求真实、长期且结构性存在。礼邦医

药聚焦肾脏病这一“沉默的大多数”，致力于为全球肾病患者提供更优质、更可及的治疗方案。

管理层寄语

礼邦医药联合创始人、首席执行官及董事会主席夏国尧博士表示：“在香港联合交易所主板上市，是礼邦医药发展历程中的重要里程碑。礼邦医药的快速成长并成功登陆香港联交所，离不开公司团队的不懈努力，亦离不开各级政府部门、投资人和各界合作伙伴的支持。立足新起点，礼邦医药将继续加速产品管线临床与商业化进程，持续升级具备全球竞争力的肾脏病一体化平台，以更优异的业绩回馈股东与合作伙伴，以更优质的肾脏病治疗方案守护全球患者。”

礼邦医药联合创始人兼首席医学官田劲医生表示：“礼邦医药致力于打破慢性肾病长期以来的治疗困境，构建了高度差异化的创新管线。目前，AP301 已完成中国 III 期注册临床试验，将于近期提交新药上市申请，有望早日为治疗高磷血症的患者提供更优的选择。同时，我们也在全力加速后续管线临床进程，推动前沿肾病治疗方案更快惠及肾脏病患者。”

关于礼邦医药

礼邦医药（09637.HK）于 2018 年初在中国上海成立，是一家聚焦肾脏病及其相关慢性疾病的综合性创新生物制药公司，主要致力于相关创新药物的发现、开发、生产和商业化，为全球慢性肾脏病及相关疾病患者提供更佳的临床治疗方案。礼邦医药已建立起丰富且均衡的肾脏病新药产品管线，包括七款在研产品及一款已上市产品（美信罗®），适应症涵盖高磷血症、肾性贫血、IgA 肾病、糖尿病肾病、局灶节段性肾小球硬化（FSGS）、常染色体显性多囊肾病（ADPKD）等。公司已在江苏扬州建成并启用生产基地，以支持 AP301 等管线产品的未来商业化，现已取得江苏省药品监督管理局颁发的药品生产许可证（B 类），并组建了肾科专科销售团队负责相关产品在中国的商业化推广。